Short Communication

69 Murine Gammaherpesvirus (MHV-68) Transforms Cultured Cells in vitro
Mrázová, V.; Betáková, T.; Kúdelová, M.; Šupolíková, M.; Lachová, V.; Lapuníková, B.; Golais, F. (Bratislava)

Original Papers

73 The Correlation between Hepatitis C Core Antigen and Hepatitis C Virus RNA Levels with Respect to Human Immunodeficiency Virus Status, Hepatitis C Virus Genotype and Interferon-Lambda-4 Polymorphism
Duy Thong, V.; Akkarathamrongsin, S.; Avihingsanon, A.; Theamboonlers, A.; Poovorawan, Y.; Tangkijvanich, P. (Bangkok)

80 HLA-B Alleles B*15:01 and B*15:02: Opposite Association with Hepatitis C Virus Infection in Chinese Voluntary Blood Donors
Xiong, H.; Huang, J.; Xiong, X. (Guangzhou); Zhang, M. (Athens, Ga.); Huang, K.; Xu, R.; Wang, M.; Li, C.; Liao, Q.; Xia, W.; Luo, G.; Ye, X. (Guangzhou); Lu, L. (Kansas City, Kans.); Fu, Y. (Guangzhou); Guo, T. (Beijing); Nelson, K. (Baltimor, Md.)

88 A Rolling Circle Amplification Screen for Polyomaviruses Other than BKPyV in Renal Transplant Recipients Confirms High Prevalence of Urinary JCPyV Shedding

95 Transcriptional Analysis of Host Responses to Marek’s Disease Virus Infection in Chicken Thymus
Hu, X.; Qin, A.; Xu, W.; Wu, G.; Li, D.; Qian, K.; Shao, H.; Ye, J. (Yangzhou)

106 High IFN-γ/IL-10 Expression Ratio and Increased Frequency of Persistent Human T-Cell Lymphotropic Virus Type 1-Infected Clones Are Associated with Human T-Cell Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis Development

115 Cytomegalovirus Glycoprotein B Genotypes in Mexican Children and Women

122 Impact of in vitro Costimulation with TLR2, TLR4 and TLR9 Agonists and HIV-1 on Antigen-Presenting Cell Activation

130 A Small Region of Porcine Hemagglutinating Encephalomyelitis Virus Spike Protein Interacts with the Neural Cell Adhesion Molecule
Potency Testing of Veterinary Vaccines for Animals: The Way From in Vivo to in Vitro

International Scientific Workshop, Langen, December 2010: Proceedings

Editor
C. Jungbäck

Contents

Preface: Jungbäck, C.

Session I:
Use of the 3R Approach for Potency (1)
Introduction: History, Approaches, Legal Situation and Political Pressure, Outlook, Expectations: Spieser, J.-M.
Potency Testing of Inactivated Rabies Vaccines Using a Serological Method: Kamphuis, E.; Krämer, B.; Schilliger, H.; Duchow, K.

Session II:
Use of the 3R Approach for Potency (2)

Session III:
In Vivo / In Vitro, a Critical Analysis
The Validation of Potency Tests: Hurdles Identified by EMA/CVMP/IWP: Woodland, R.
In Vitro Antigen Measurement and Potency Tests: Challenges Encountered During Method Development… and Lessons Learned: Kubiak, V.
In Vitro Potency Tests: Challenges Encountered During Method Development: Yomuya, C.; Thiel, H.J.; König, M.
AlphaLISA® Assays to Improve the Vaccine Development Process: Cosentino, G.

Session IV:
Consistency as an Alternative to Potency
Consistency as Tool to Support in Vitro Batch Potency Testing in GMP Production: Stirling, C.
Consistency as an Alternative to Potency Testing: Duchow, K.
Sirota, L.A.
Appropriateness of in Vitro Potency Tests or Consistency Tests for Vaccine Stability Studies: Pfannenstiel, M.A.; Inman, M.

Workshop Summary
Workshop presentations not in this publication

Participants
Index of Authors
Developments in Biological Standardization
Developments in Biologicals

KARGER
Developments in Biologicals, Vol. 134
Edited by the International Association for Biologicals (IABS)
ISSN 1424–6074

Potency Testing of Veterinary Vaccines for Animals: The Way From in Vivo to in Vitro
International Scientific Workshop, Langen, December 2010: Proceedings
Editor: Jungbäck, C. (Langen)
X = 164 ps, 36 fg., 10 tabs, soft cover, 2012
CHF 105.– / EUR 88.– / USD 124.00
Prices subject to change
EUR price for Germany, USD price for USA only

Please send: ______ copies

Postage and handling free with prepayment

Payment:
Please charge to my credit card
☐ American Express ☐ Diners
☐ MasterCard ☐ Visa

Card No.:
Exp. date:
CVV/CVC
(3 digits in the signature field on the back of Visa and MasterCard)
☐ Check enclosed ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
E-Mail orders@karger.ch, www.karger.com

Fax: +41 61 306 12 34

Name/Address:

Date:

Signature:
Guidelines for Authors

Submission
Only original papers written in English are considered and should be submitted online at:
www.karger.com/int

You should experience problems with your submission, please contact:
S. Karger AG
Editorial Office Intervirology
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1344
Fax +41 61 306 1434
E-Mail int@karger.ch
Names, postal and e-mail addresses of three experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publisher. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Intervirology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Studies involving human subjects: Authors of articles based on trials in humans must first obtain approval from an independent national ethics committee. In addition, a statement that research has been carried out in accordance with the Helsinki Declaration, signed by all authors, must be submitted to the Editorial Office along with the submitted paper.

Consent of patients: If there is any chance that a patient may be identified from an illustration, we ask for the written consent of the patient for publication (or where appropriate from his/her relatives or guardian). Data relating to anonymized tissue and other samples will not normally be considered to be personal information. Publication of research findings connected with such samples does not require patient consent.

Studies involving animals: An article based on trials performed on animals requires a statement that approval from an independent ethics committee has been obtained, signed by all authors.

The Editor-in-Chief recommends that approvals and informed consent, where appropriate, are also declared in the article itself, preferably in the Materials and Methods section.

Arrangement
Lines should be numbered in the margin.

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 200 words structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Body of the paper: Manuscripts should then be divided into the following subdivisions: Introduction, Materials and Methods (as brief as possible), Results, Discussion, Acknowledgments and References.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, present several illustrations en bloc for reproduction (max. size 180 × 223 mm) or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples:
(b) Books published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

Nomenclature of viruses
Names used for viruses should be those approved by the International Committee on Taxonomy of Viruses (ICTV) and published in Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds): Virus Taxonomy, VIIIth Report of the International Committee on Taxonomy of Viruses, ed 2, revised (New York, Academic Press, 2005). If desired, synonyms may be added in parentheses when the name is first mentioned. Approved generic (or group) and family names should also be used.

Short Communications
In addition to regular papers, a section of the journal will publish brief communications of important findings, in which illustrative material should be limited. Such notes should include a brief summary and key words, the body of the report (without any subdivisions), brief acknowledgments, and a few selected references. The general style and submission procedures outlined above apply to the short communication.

Commentaries
Short commentaries of an editorial nature may be submitted to the journal. In these communications, usual manuscript subdivisions do not apply, and a summary statement is not needed; however, a very brief reference list may be included.

Letters to the Editor
This section provides readers with a forum in which to exchange ideas and comments on papers published in the journal. Letters should be no longer than 1–1½ double-spaced pages, including a maximum of six references, and do not require abstracts or formal section headings.

Page Charges
There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a page is equal to approx. 16 manuscript pages (including tables, illustrations and references).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
**Standard forms of abbreviations:** The standard abbreviations used for measurements of weight, length, volume, and time (i.e., mg, cm, ml, and min) are acceptable and may be used without definition. The abbreviations listed also require no preliminary definition. Please note that punctuation is not needed. When using other abbreviations, the name should be spelled out in full at the first mention, and followed with the abbreviation in parentheses.

- ° = degree centigrade
- (Fahrenheit will not be used)
- A, C, G, T, U = adenine, cytosine, guanine, thymine, uracil
- AMP = 5'-monophosphates of adenosine
- CMP = cytidine
- GMP = guanosine
- TMP = thymidine
- UMP = uridine
- ADP, etc. = adenosine 5'-diphosphate, etc.
- ATP, etc. = adenosine 5'-triphosphate, etc.
- CPE = cytopathic effect
- DEAE-cellulose = diethylaminoethylcellulose
- DNA = deoxyribonucleic acid
- DNase = deoxyribonuclease
- EDTA = ethylenediaminetetra-acetate
- EOF = efficiency of plating
- g = acceleration of gravity
- ID₅₀ = median infective dose
- LD₅₀ = median lethal dose
- m = molar
- MEM = minimum essential medium
- MOI = multiplicity of infection
- n = normal
- ng = nanogram
- nm = nanometer (10⁻⁹ m)
- PAGE = polyacrylamide gel electrophoresis
- PFU = plaque forming units
- RNA = ribonucleic acid
- RNAse = ribonuclease
- rpm = revolutions per minute
- SD = standard deviation
- SDS = sodium dodecyl sulfate
- sp gr = specific gravity
- TCD₅₀ = median tissue culture infective dose
- Tris = tris (hydroxymethyl)
- Tris (hydroxymethylamino)methane (2-aminomethyl-1,3-propanediol)
- UV = ultraviolet
- V = volt
- W = watt

---

**NIH-Funded Research**
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available at [http://publicaccess.nih.gov/policy.htm](http://publicaccess.nih.gov/policy.htm)

**Self-Archiving** Karger permits authors to archive their pre-prints (i.e., pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

**Proofs** Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

**Reprints** Order forms and a price list are sent to the author with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

---

Take a guided tour through 125 years of medical and scientific publishing

This hand-picked selection represents the history of the publishing house and illustrates the development of medicine and its subspecialties:

[www.karger.com/Publishing-Highlights](http://www.karger.com/Publishing-Highlights)
Contents

See the journal website for contents
67th Annual Conference of the Germany Society of Hygiene and Microbiology

2015

27–30 September 2015

Halle Münsterland • Münster

Conference Chairs
Prof. Dr. rer. nat. Dr. h. c. Helge Karch
Prof. Dr. med. Georg Peters
University of Münster
University Hospital

Main Topics
• Hospital Hygiene and Public Health
• Infection – Toxins, Invasins and Glycosylation
• NGS for Microbial Genomic Surveillance and Beyond – One Technology Fits All
• TLR and Inflammasome
• Zoonoses (Viruses, Bacteria and Parasites)

Deadline Early Bird Registration
31 July 2015
Therapy of Hepatitis B Virus Infections – Potential and Limitations

Editors
W.H. Gerlich
D. Glebe
L.G. Gürtler
R. Kaiser

Although the beginnings of hepatitis B therapy date back to 1976, it has only been in the last 10 years that it has gradually reached a satisfactory level of efficacy and dependency. According to the latest studies, many cases of chronic hepatitis B may need life-long therapy while others may reach, after several years, a kind of cure mediated by the host immune system. The main purpose of hepatitis B virus therapy is the prevention of the life-threatening late complications like liver cirrhosis and hepatocellular carcinoma, but it is also increasingly gaining a place in severe acute hepatitis and in the prevention of reactivation or transmission of the infection in various settings. This special issue of Intervirology contains contributions from internationally renowned virologists and hepatologists who describe these additional applications. Furthermore, the remaining problems and the latest approaches to overcome them are discussed. Primarily addressing clinical virologists and hepatologists, this publication is also relevant for those who are interested in therapy and prevention of infectious diseases, including public health specialists.

Contents
Preface

Background on Hepatitis B Virus
• Molecular Virology of Hepatitis B Virus and Targets for Antiviral Intervention: Glebe, D.; König, A.
• Genotypes and Genetic Variability of Hepatitis B Virus: Kramvis, A.

Therapeutic Targets
• Inhibitors of Hepatitis B Virus Attachment and Entry: Lempp, F.A.; Urban, S.
• Host Factor-Targeted Hepatitis B Virus Therapies: Gehring, A.; Bertoletti, A.; Tavis, J.E.

Clinical Applications
• Therapy of Hepatitis B Virus Infections: Potential and Limitations: Brunetto, M.R.; Bonino, F.
• Antiviral Therapy of Chronic Hepatitis B: van Bömmel, F.
• Therapy of Acute and Fulminant Hepatitis B: Tillmann, H.L.; Patel, K.
• Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation: Raimondo, G.; Filomia, R.; Maimone, S.
• Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients: Roche, B.; Samuel, D.
• Reduction of Infectivity in Chronic Hepatitis B Virus Carriers among Healthcare Providers and Pregnant Women by Antiviral Therapy: Gerlich, W.H.
• Effect of Antiretroviral HIV Therapy on Hepatitis B Virus Replication and Pathogenicity: Gürtler, L.G.

Resistance
• Mechanisms of Hepatitis B Virus Resistance Development: Warner, N.; Locarnini, S.
• Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants: Glebe, D.; Geipel, A.
• Hepatitis B Virus Drug Resistance Tools: One Sequence, Two Predictions: Neumann-Fraune, M.; Beggel, B.; Kaiser, R.; Obermeier, M.

Author and Subject Index

The easiest way to order: www.karger.com/int
The *Journal of Innate Immunity* is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of 'danger', microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications and reviews.

**Journal of Innate Immunity**  
Founded: 2008  
Category: Basic and Clinical Research  
Field of Interest: Immunology  
Listed in bibliographic services, including Pubmed/MEDLINE, Web of Science  
2015: Volume 7  
6 issues per volume  
Language: English  
ISSN 1662–811X  
e-ISSN 1662–8128  
Impact Factor: 4.557

**Selected contributions**  
- Mast Cell-Deficient KitW-Sh Mice Develop House Dust Mite-Induced Lung Inflammation despite Impaired Eosinophil Recruitment: de Boer, J.D.; Yang, J.; van den Boogaard, F.E.; Hoogendijk, A.J.; de Beer, R.; van der Zee, J.S.; Roelofs, J.J.T.H.; van ‘t Veer, C.; de Vos, A.F.; van der Poll, T. (Amsterdam)  
- Mycobacterium tuberculosis-Induced Neutrophil Extracellular Traps Activate Human Macrophages: Braian, C.; Hogue, V.; Stendahl, O. (Linköping)  
- Control of Myeloid Cell Trafficking in Resolution: Norling, L.V.; Perretti, M. (London)  
- Cystic Fibrosis Transmembrane Conductance Regulator Recruitment to Phagosomes in Neutrophils: Zhou, Y.; Song, K.; Painter, R.G.; Aiken, M. (New Orleans, La.); Reiser, J. (Bethesda, Md.); Stanton, B.A. (Hanover, N.H.); Nauseef, W.M. (Coralville, Iowa); Wang, G. (New Orleans, La.)  

More information at [www.karger.com/jin](http://www.karger.com/jin)
Karger Publishers – independent, family-run
and Swiss-based.

It is our goal to serve the global scientific community with innovative and outstanding publications in all fields of medical science. This means dedication to maintaining the highest standards of quality, as well as personalized service for authors, editors and readers.

www.karger.com

Please order a free copy of the Karger Festschrift ‘Connecting the World of Biomedical Science’ by sending your address to 125years@karger.com.